Administration of gedunin suppressed the development of BPH carcinomas by inhibiting the PI3K/Akt and NF-κB pathways by inactivating Akt and the inhibitory kappa B kinase (IKK), respectively. The gene discussed is AKT1; the disease is benign prostatic hyperplasia.